FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number	3235-0287								
Estimated ave	rage burden								
hours per resp	oonse: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of 3 THOM.	<u>BI</u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [ BCRX ]										neck a	all appli Directo Officer	cable) or (give title	ig Per	10% O	wner				
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					05/	3. Date of Earliest Transaction (Month/Day/Year) 05/22/2017											below) below) Senior Vice President and CFO					
(Street)  DURHA  (City)		tate)	27703 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)									Lin	ie) X	Form f Form f Persor	ral or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
		Tab	le I - No	n-Deriv	ative	e Se	curit	ies A	cqu	ıired, I	Disp	osed o	of, or	Bene	eficia	lly O	wnec	1				
D D				Date	2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)			tion istr.					and Securition Benefici Owned I		es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
									ĺ	Code	v	Amount	0	(A) or (D)	Price	Reporte Transac (Instr. 3		tion(s)			(Instr. 4)	
Common	Stock			05/22	2/201	7				М		7,750	0	A \$4.		'3	149,210		D			
Common Stock <sup>(1)</sup>				05/22	2/201	7				F		6,996	6	D	\$5.2	4	142,214			D		
		٦	able II -	Deriva (e.g., p	tive :	Sec call	uritie s, wa	s Acc arrant	quir s, c	red, Di option:	spo s, c	sed of onverti	, or E ble s	Benef ecuri	icially	y Ow	ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		of Der Sec Acc (A) Dis of (	posed D) str. 3, 4	Ex	Date Exe piration I onth/Day	Date		Amou Secu Unde Deriv	7. Title and Amount of Securities Underlying Derivative Secui (Instr. 3 and 4)		Deri Secu	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da: Exc	ite ercisable		piration ate	Title	0 N 0	amount or lumber of Shares							
Emp. Stock Option (Right to Buy)	\$4.73	05/22/2017			M			7,750	03	3/01/2013	03	3/01/2022	Comr Stoo		7,750		\$0	4,000		D		

## Explanation of Responses:

1. Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.

/s/ Alane P. Barnes, by power of attorney

05/24/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.